Recombinant virus with diminished latency and methods of using same
AssigneeThe United States of America, as represented by the Secretary, Department of Health and Human Services
InventorsJeffrey I. Cohen, Lesley Pesnicak
Life of this patent
Estimating the term…
Abstract
The disclosure provides recombinant herpes virus with diminished latency. In embodiments, the recombinant herpes virus comprises a latency gene or transcript linked to an altered or heterologous promoter. The disclosure also provides compositions and methods for inducing immunity in animals using the recombinant herpes viruses.
Claims13
A method for making an attenuated live virus having an impaired ability to establish latency, comprising:
- introducing a recombinant virus comprising all or a portion of a herpes virus genome into a host cell to produce an amount of the recombinant virus suitable for a vaccine, wherein the recombinant virus genome comprises a promoter for a latency gene or transcript that is altered or modified, and the gene or transcript is expressed from the recombinant virus genome during viral replication;
- and
- recovering the recombinant virus from the host cell.
A method for making an attenuated live virus having an impaired ability to establish latency, comprising:
- introducing a recombinant virus comprising all or a portion of a herpes virus genome into a host cell to produce an amount of the recombinant virus suitable for a vaccine, wherein the recombinant virus genome comprises a latency gene or transcript and the latency gene or transcript is at a different location in the genome relative to its native location;
- and
- recovering the recombinant virus from the host cell.
Dependencies are inferred from the claim text.